Blood cancer journal · 2021
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage.
СтатьяПоддержка исследования: вне правительства СШАConsensus StatementНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fernández de Larrea Carlos, Kyle Robert, Rosiñol Laura, Paiva Bruno, Engelhardt Monika, Usmani Saad, Caers Jo, Gonsalves Wilson, Schjesvold Fredrik, Merlini Giampaolo, Lentzch Suzanne, Ocio Enrique, Garderet Laurent, Moreau Philippe, Sonneveld Pieter, Badros Ashraf, Gahrton Gösta, Goldschmidt Hartmut, Tuchman Sascha, Einsele Hermann, Durie Brian, Wirk Baldeep, Musto Pellegrino, Hayden Patrick, Kaiser Martin, Miguel Jesús San, Bladé Joan, Rajkumar S Vincent, Mateos Maria Victoria
Аннотация
Primary plasma cell leukemia (PCL) has a consistently ominous prognosis, even after progress in the last decades. PCL deserves a prompt identification to start the most effective treatment for this ultra-high-risk disease. The aim of this position paper is to revisit the diagnosis of PCL according to the presence of circulating plasma cells in patients otherwise meeting diagnostic criteria of multiple myeloma. We could identify two retrospective series where the question about what number of circulating plasma cells in peripheral blood should be used for defining PCL. The presence of ≥5% circulating plasma cells in patients with MM had a similar adverse prognostic impact as the previously defined PCL. Therefore, PCL should be defined by the presence of 5% or more circulating plasma cells in peripheral blood smears in patients otherwise diagnosed with symptomatic multiple myeloma.